合并使用他汀类药物对非肌层浸润性膀胱癌患者的潜在获益
该回顾性队列纳入2001至2020年接受膀胱内卡介苗(BCG)辅助免疫治疗的2602例非肌层浸润性膀胱癌(NMIBC)患者,比较他汀组与无他汀组生存结局。中位随访11.0年,他汀组总生存(OS)、肿瘤特异性生存(CSS)和无进展生存(PFS)均显著更优;BCG前启动他汀是OS和CSS的独立保护因素,但对无复发生存(RFS)和PFS无独立保护作用。
要点
- 他汀组OS、CSS、PFS在Kaplan-Meier分析中均显著优于无他汀组(均P<0.001)。
- BCG前启动他汀是OS(HR 0.607,95%CI 0.514-0.716)和CSS(HR 0.571,95%CI 0.376-0.868)的独立保护因素。
- BCG前启动他汀对RFS(HR 0.885,95%CI 0.736-1.065)和PFS(HR 0.689,95%CI 0.469-1.013)无独立保护作用。
核心结论
- 他汀类药物治疗似乎对接受膀胱内BCG辅助治疗的NMIBC患者的OS和CSS具有保护作用。
研究设计与样本
- 回顾性队列研究,纳入2001至2020年接受膀胱内BCG治疗且记录他汀处方的连续NMIBC患者2602例。
- 比较他汀组与无他汀组的OS、CSS、RFS和PFS,采用Kaplan-Meier法和多因素Cox回归分析。
主要发现
- 中位随访11.0年。
- Kaplan-Meier分析显示他汀组OS(P<0.001)、CSS(P<0.001)和PFS(P<0.001)均显著优于无他汀组。
- 亚组分析显示BCG治疗前开始他汀治疗者CSS(P=0.02)和PFS(P<0.01)更优。
- 多因素Cox回归中,BCG前他汀组是OS的独立保护因素(HR 0.607,95%CI 0.514-0.716)。
- 多因素Cox回归中,BCG前他汀组是CSS的独立保护因素(HR 0.571,95%CI 0.376-0.868),但对RFS(HR 0.885,95%CI 0.736-1.065)和PFS(HR 0.689,95%CI 0.469-1.013)无独立保护作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy. PATIENTS AND METHODS: A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression. RESULTS: A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013). CONCLUSIONS: Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.
引用
- Liu K, Nicoletti R, Zhao H, et al. The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer. BJU Int. 2024. PMID: 39257199. doi:10.1111/bju.16493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。